Barini E, Plotzky G, Mordashova Y, Hoppe J, Rodriguez-Correa E, Julier S, LePrieult F, Mairhofer I, Mezler M, Biesinger S, Cik M, Meinhardt M, Ercan-Herbst E, Ehrnhoefer DE, Striebinger A, Bodie K, Klein C, Gasparini L, Schlegel K. Tau in the brain interstitial fluid is fragmented and seeding-competent. Neurobiol Aging. 2022 109:64-77.
Eichentopf L, Hiemke C, Conca A, Engelmann J, Gerlach M, Havemann-Reinecke U, Hefner G, Florio V, Kuzin M, Lieb K, Reis M, Riemer TG, Serretti A, Schoretsanitis G, Zernig G, Gründer G, Hart XM. Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy. Front Psychiatry. 2022 13:972141.
Foo JC, Meinhardt M, Skorodumov I, Spanagel R. Alcohol solution strength preference predicts compulsive-like drinking behaviour in rats. Alcohol Clin Exp Res. 2022 46(9):1710-1719. Epub 2022 Jul 24.
Funk CSM, Hart XM, Gründer G, Hiemke C, Elsner B, Kreutz R, Riemer TG. Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors. Front Psychiatry. 2022 13:826138.
Gaebler AJ, Finner-Prével M, Lammertz S, Schaffrath S, Eisner P, Stöhr F, Röcher E, Winkler L, Kaleta P, Lenzen L, Augustin M, Hovancakova J, Schwemmer L, Stormanns E, Keskin F, Hendricks F, Paulzen M, Gründer G, Schneider F, APIC Consortium , Mathiak K. The negative impact of vitamin D on antipsychotic drug exposure may counteract its potential benefits in schizophrenia. Br J Clin Pharmacol. 2022 88(7):3193-3200. Epub 2022 Feb 14.
Gründer G, Brand M, Kärtner L, Scharf D, Schmitz C, Spangemacher M, Mertens L. [Are psychedelics fast acting antidepressant agents?]. Nervenarzt. 2022 93(3):254-262. Epub 2022 Feb 1.
Hart X, Hiemke C, Eichentopf L, Lense XM, Clement HW, Conca A, Faltraco F, Florio V, Grüner J, Havemann-Reinecke U, Molden E, Paulzen M, Schoretsanitis G, Riemer TG, Gründer G. Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis. Psychopharmacology (Berl). 2022 239(11):3377-3391. Epub 2022 Oct 5.
Hart X, Schmitz CN, Gründer G. Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice. Front Psychiatry. 2022 13:832209.
Kossmann C, Heller J, Brüne M, Schulz C, Heinze M, Cordes J, Mühlbauer B, Rüther E, Timm J, Gründer G, Juckel G. Correction to: Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia. Psychiatr Q. 2022 93(2):701-702. Epub 2022 Mar 12.
Pfeifer P, Sebastian A, Buchholz HG, Kaller CP, Gründer G, Fehr C, Schreckenberger M, Tüscher O. Prefrontal and striatal dopamine D/D receptors correlate with fMRI BOLD activation during stopping. Brain Imaging Behav. 2022 16(1):186-198. Epub 2021 Aug 17.
Schmidt-Kraepelin C, Feyerabend S, Engelke C, Riesbeck M, Meisenzahl-Lechner E, Verde PE, Correll CU, Kluge M, Makiol C, Neff A, Lange C, Englisch S, Zink M, Langguth B, Poeppl TB, Reske D, Gouzoulis-Mayfrank E, Gründer G, Hasan A, Brockhaus-Dumke A, Jäger M, Baumgärtner J, Leucht S, Cordes J, COMBINE Study Group . Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. Lancet Psychiatry. 2022 9(4):291-306.
Schoretsanitis G, Haen E, Piacentino D, Conca A, Endres K, Hiemke C, Gründer G, Paulzen M. Effects of body weight, smoking status and sex on plasma concentrations of once-monthly paliperidone palmitate. Expert Rev Clin Pharmacol. 2022 15(2):243-249. Epub 2021 Dec 27.
de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopecek M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, Las Cuevas C, Cohen D, Schulte PFJ, Ertuğrul A, Yağcıoğlu AEA, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Rădulescu FŞ, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubała WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ristic DI, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Saffian SM, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry. 2022 55(2):73-86. Epub 2021 Dec 15.